Industrifonden new major shareholder in InDex Pharmaceuticals

Industrifonden invests MSEK 40 and becomes a new shareholder in InDex
Pharmaceuticals, which develops Kappaproct – a drug for treatment of severe
inflammatory bowel disease. Current shareholders, including SEB Venture Capital,
invest an additional MSEK 35. The financing will in large be used to conduct a clinical
phase III trial using Kappaproct with the aim of obtaining market approval.

Investor contact

Peter Zerhouni
Peter Zerhouni
+46 8 122 038 50